Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251498 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Veeda Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00251498 is a Phase 2 study that has completed, run by Veeda Oncology. The registered enrollment target is 82 participants.
The verdict
NCT00251498, a Phase 2 study, has completed, sponsored by Veeda Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the efficacy (response rate) of cetuximab when administered in combination with docetaxel and carboplatin for treatment of patients with advanced non-small cell lung cancer. The secondary objectives of this study are: * to determine the time to progression and overall survival for patients with advanced NSCLC who are treated with the combination docetaxel, carboplatin , and cetuximab * to determine the toxicity of the combination in patients with advanced NSCLC. Patients with stages IIIB (pleural or pericardial effusion) and IV NSCLC who have not received any prior chemotherapy will be eligible to participate in the trial. Other eligibility criteria include: ECOG PS 0-1, normal hepatic and renal function, age \>18 years. Specific inclusion and exclusion criteria are detailed in Sections 4.2 and 4.3.
Interventions
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251498
The ClinicalTrials.gov registry entry for NCT00251498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veeda Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00251498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251498 about?
NCT00251498 is a clinical study titled "Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer". The primary objective of this study is to determine the efficacy (response rate) of cetuximab when administered in combination with docetaxel and carboplatin for treatment of patients with advanced non-small cell lung cancer. The secondary objectives of this study are: * to determine the time to p...
What is the current status of trial NCT00251498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00251498?
The interventions under investigation include: Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00251498?
This trial is sponsored by Veeda Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.